IRAK3

Across TCGA pan-cancer cohorts, IRAK3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IRAK3 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IRAK3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRAK3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where IRAK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.922	0.219	<.001	42	view →
UCEC	DFS	Median	III,IV	1.000	0.433	.008	26	view →
LUAD	OS	Median	III,IV	0.233	0.782	.003	24	view →
LSCC	DFS	Median	II,III,IV	0.636	0.926	.001	17	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IRAK3–PDAC (DFS)

Open the PDAC breakdown →